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In Response:
Thank you for the special atten-
tion on our article. Yes, in our article,
we wanted to simply stress the impor-
tance of appropriate patient selection to
minimize the risk of interstitial lung dis-
ease (ILD) with epidermal growth factor
receptor tyrosine kinase inhibitor rather
than the difference itself in the incidence
of ILD with both agents. Indeed, one can
also obtain the similar observation in a
previous Japanese study.1 This shows
that the incidence of ILD has decreased
over years in the gefitinib treatment for
Japanese cohort with 3.0 and 1.4% in
2002 and 2008, respectively.
We sincerely apologize for the in-
correct description of the proportion of
poor performance status patients treated
with gefitinib monotherapy, as Dr. Jones
and colleagues suggested. We, medical
oncologists, truly applaud the great ef-
forts of AstraZeneca company and thank
for the refined and updated proscribing
information for gefitinib. Thanks to this,
we can now properly make the appropriate
patient selection and can obtain the ex-
cellent data showing the safety and ef-
fectiveness of gefitinib monotherapy in
the first-line setting in the selected pa-
tient population.2
Katsuyuki Hotta, MD, PhD
Nagio Takigawa, MD, PhD
Katsuyuki Kiura, MD, PhD
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